stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Return on equity
Dr. Reddy's Laboratories Ltd's return on equity over the twelve months to 30 September 2026 was 6.60%, down 4.8 percentage points from fiscal 2026 (11.4%). Over the past ten years it has ranged from 7.83% (fiscal 2018) to 21.6% (fiscal 2024); the current reading is higher than 33% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 11.4% | (6.73) |
| FY2025 | 18.1% | (3.50) |
| FY2024 | 21.6% | 1.03 |
| FY2023 | 20.6% | 7.84 |
| FY2022 | 12.8% | 2.08 |
| FY2021 | 10.7% | (2.01) |
| FY2020 | 12.7% | (1.01) |
| FY2019 | 13.7% | 5.87 |
| FY2018 | 7.83% | (1.83) |
| FY2017 | 9.66% | (6.56) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.4% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd | 6.60% |
| ALKS Alkermes plc compare | −0.02% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement